Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Recombinant Human Chymotrypsin
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : Healthgen Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant Human Chymotrypsin is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastric Mucosal Lesion.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Recombinant Human Chymotrypsin
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : Healthgen Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NCR300
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Nuwacell Biotechnologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NCR300 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 04, 2024
Lead Product(s) : NCR300
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Nuwacell Biotechnologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tislelizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer
Details : Tislelizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rectal Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 18, 2022
Lead Product(s) : Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People’s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.
Details : Capecitabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 03, 2021
Lead Product(s) : Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People’s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Recipient : CSPC Baike
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
Details : Pegfilgrastim is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Lymphohistiocytosis, Hemophagocytic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 05, 2020
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Recipient : CSPC Baike
Deal Size : Inapplicable
Deal Type : Inapplicable
Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)
Details : Autologous Tcm Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 14, 2018
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
Details : Donepezil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 01, 2016
Lead Product(s) : Tauroursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Beijing Trendful Kangjian Medical Information Consulting Limited Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tauroursodeoxycholic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Liver Cirrhosis, Biliary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 20, 2013
Lead Product(s) : Tauroursodeoxycholic Acid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Beijing Trendful Kangjian Medical Information Consulting Limited Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
